Beas-Jiménez, J. de D.; López-Lluch, G.; Sánchez-Martínez, I.; Muro-Jiménez, A.; Rodríguez-Bies, E.; Navas, P.

Sarcopenia: implications of physical exercise in its pathophysiology, prevention and treatment
Revista Andaluza de Medicina del Deporte, vol. 4, núm. 4, diciembre, 2011, pp. 158-166
Centro Andaluz de Medicina del Deporte
Sevilla, España

Available in: http://www.redalyc.org/articulo.oa?id=323327668005
Sarcopenia: implications of physical exercise in its pathophysiology, prevention and treatment

J. de D. Beas-Jiménez\textsuperscript{a}, G. López-Lluch\textsuperscript{b}, I. Sánchez-Martínez\textsuperscript{a}, A. Muro-Jiménez\textsuperscript{c}, E. Rodríguez-Bies\textsuperscript{b} and P. Navas\textsuperscript{b}

\textsuperscript{b}Andalusian Center of Developmental Biology. Pablo de Olavide University. CSIC. Department of Physiology, Anatomy and Cell Biology. CIBERER. Carlos III Institute. Seville. Spain.

\textbf{ABSTRACT}

Sarcopenia is known as a progressive muscle wasting produced as years accumulate and characterized by a progressive loss of muscle mass and strength, increase of muscle fat and progressive decline of functional capacity. This process produces important and severe effects on quality of life in elderly people since sarcopenia is the most frequent cause of discapacity, dependency and increase or morbi-mortality. In the present review we analyze the different etiological factors and the prevention and treatment strategies against sarcopenia. One of the main strategies is the strength training that, added to an adequate nutrition, plays a primordial role in prevention and progression of sarcopenia.

© 2011 Revista Andaluza de Medicina del Deporte.

\textbf{RESUMEN}

Sarcopenia: implicaciones del ejercicio físico en su fisiopatología, prevención y tratamiento

Se conoce como sarcopenia al progresivo deterioro muscular que se produce con el paso de los años y que se caracteriza por una pérdida progresiva de fuerza y masa musculares, aumento de la grasa muscular y el deterioro progresivo de la capacidad funcional. Este proceso tiene importantes repercusiones en la calidad de vida de las personas mayores, ya que es causa frecuente de discapacidad, dependencia y aumento de la morbimortalidad. En la presente revisión bibliográfica del tema, analizamos los diferentes factores etiológicos y las estrategias de prevención y tratamiento de la sarcopenia, entre las que el ejercicio, y en particular el entrenamiento de fuerza, junto con una alimentación adecuada, desempeñan un papel primordial.

© 2011 Revista Andaluza de Medicina del Deporte.

\textbf{Correspondence:}
J. de D. Beas-Jiménez. Centro Andaluz de Medicina del Deporte. Consejería de Turismo, Comercio y Deporte de la Junta de Andalucía. Glorieta Beatriz Manchón, s/n. 41092 Sevilla. Spain. E-mail: juand.beas@juntadeandalucia.es
Introduction

After reaching adulthood, humans and most mammals suffer a progressive decline of strength and muscle mass as time goes by. This is accompanied by a functional capacity loss and a raise of fat in muscle. Importantly, all these factors affect quality of life of the elderly causing frailty, dependency and the increase of morbi-mortality. This progressive deterioration of muscle capacity is known as sarcopenia (From the Greek: sarco: muscle and penia: wasting, loss). In a classical way, an individual was considered as suffering sarcopenia when muscle parameters values were lower than two standard deviations from the values of a referenced young population. However, the current tendency includes in the definition of sarcopenia some other parameters related to strength, functional capacity of the subject and corporal fat amount. This tendency distinguishes between an aging-dependent process (primary sarcopenia) and a pathological process (secondary sarcopenia). New concepts such as dinapenia or the age-associated loss of strength or new techniques such as proteomics or genomics must be considered in future studies of this pathology.

Etiology and particular characteristics of sarcopenia in the elderly

Several authors indicate that muscle mass reaches the maximum amount around the 30s and after that, it declines at a rate of 3-8% per decade. Decline rhythm accelerates from the 50s reaching 12-15% per decade. Women show a higher decrease of muscle mass, especially after menopause. Regarding muscle quality, the capacity to produce strength per unit of muscle, different longitudinal studies have reported an important decrease during aging. European population data about sarcopenia prevalence in people older than 65 years indicate a ratio moving from 9.5 to the 15.7%. These values rise as the population get older. When compared with woman showing normal bone mineral density (0.8%), sarcopenia is more frequent in women suffering osteopeny (25%) and osteoporosis (50%). This relationship is probably due to related etiological mechanisms. Furthermore, we can speculate that physical activity, able to maintain muscle mass, will help to maintain bone mass. This effect will be especially good in women since they show higher osteoporosis prevalence.

The reduction of muscle mass in aged people does not affect in the same way to arms and legs. Muscle wasting is higher in lower limbs with independency of the sex of the person. However, when functional parameters, such as muscle quality, are taken into consideration, we can find sex-dependent differences. Men suffer a higher loss in upper limbs than women whereas no differences in the deterioration of muscle mass rate in lower limbs have been found. These differences could be due to the fact that women are more able to maintain a higher activity in arms due to domestic duties. Reduction of muscle mass in lower limbs is, however, more important since it produces a severe functional decline in people’s capacity. Aging-related sarcopenia seems to depend on the chronic inflammation process affecting most of the elderly, aggravated by fat infiltration in the muscle and sarcopenic obesity. Sarcopenic obesity is characterized by the pathological increase of body fat accompanied by a decrease in muscle and bone mass. In these patients, excessive amount of calories in the diet produces a higher loss of muscle mass. Obesity seems to contribute, even more than sarcopenia, to the lower functional capacity of these subjects. Further, co-morbid diseases common to older individuals such as cancer, kidney disease, diabetes and peripheral artery disease can also accelerate the progression of sarcopenia in elderly people.

Two mechanisms are involved in the decrease of the muscle mass in humans: reduction of the number of muscle fibres and reduction of the cross-sectional area of existing fibres. Aging does not affect in the same way to all the types of fibres. Type II fibres are the most affected. In consequence, important functional incapacity appears due to the decrease of production of rapid strength or to carry out power in muscle. This is due to the lower resistance of this kind of fibres to the denervation, deficiencies in gene expression of myosin type II and a lower resistance of these fibres to oxidative stress. All these mechanisms could be related to testosterone deficit found in old people.

Reduction of muscle fibre mass is also produced by intrinsic factors in myocytes. In aged people muscle mitochondria dysfunction accumulates. This deleterious effect is caused by accumulation of mtDNA damage that negatively affects the metabolic rate, protein synthesis and ATP production. All these effects end in the death of the muscle fiber. Moreover, regeneration and repair mechanisms of muscle fibre are also compromised in elderly people due to a lower activity of satellite cells, chronic inflammation, oxidative stress, abnormal response of the microRNA and an inadequate regulation of the repair processes in damaged muscle fibres.

Aged muscle is characterized by a delay in the peak of muscle contraction, an increase in the time of muscle relaxation, diminution in strength and reduction of the oxidative metabolic capacity. These alterations are due to the accumulation of oxidative stress damaged proteins and DNA, especially mtDNA, mitochondrial dysfunction, alteration of the transport of calcium and malfunction of contractile proteins. Disappearance of muscle fibres forces to surviving fibres to compensate, or partially correct the compelled deficit to maintain the optimal capacity to generate strength.

All these reasons permit us to affirm the multifactorial etiology of sarcopenia. The different concerned mechanisms involved in muscle loss are indicated in table 1 and figure 1.

Prevention and treatment of sarcopenia

Physical exercise, nutrition and pharmacological approaches have been proposed as mechanisms for and treatment of sarcopenia. However, to date, no pharmacological procedures have demonstrated any efficiency in the prevention of sarcopenia in humans. This pharmacological inefficacy must be due to the complexity of sarcopenia. For this reason, clinical trials of drug testing for treatment of sarcopenia must include significant improvement of physical performance, falls, fractures and functionality and quality of life.

Preventive measures must be maintained during the whole life of the person. These measures consist in the practice of regular resistant and aerobic exercise and an equilibrated diet. These mechanisms require the increment of the uptake of high-quality proteins, showing fast absorption and high contents of leucine, adequate uptake of antioxidants, caloric restriction and reduction of the deficit of vitamin D or inappropriate loss of weight. Nutritional measures are of special interest because elderly people showing recurrent pathologies or in the case of sarcopenia-suffering obese old people, reduce physical
Table 1
Main etiological mechanisms involved in sarcopenia

<table>
<thead>
<tr>
<th>Mechanism</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nervous</td>
<td>Reduction of the number of α/β motoneurons</td>
</tr>
<tr>
<td></td>
<td>Reduction of the number of motor units</td>
</tr>
<tr>
<td></td>
<td>Decrease of the nervous transmission speed</td>
</tr>
<tr>
<td></td>
<td>Demyelination</td>
</tr>
<tr>
<td></td>
<td>Reinervation after lost of motoneurons</td>
</tr>
<tr>
<td></td>
<td>Reduction of the coupling excitation-contraction</td>
</tr>
<tr>
<td></td>
<td>Deficient coordination of agonists-antagonists</td>
</tr>
<tr>
<td></td>
<td>Reduction of the neuromuscular activation capacity</td>
</tr>
<tr>
<td></td>
<td>Decrease of fibre number</td>
</tr>
<tr>
<td></td>
<td>Decrease of muscle quality</td>
</tr>
<tr>
<td></td>
<td>Reduction of proliferation of satellite cells</td>
</tr>
<tr>
<td></td>
<td>Impairment of repair and regeneration processes</td>
</tr>
<tr>
<td></td>
<td>IGF-I resistance</td>
</tr>
<tr>
<td></td>
<td>Fat infiltration</td>
</tr>
<tr>
<td></td>
<td>Mitochondrial dysfunction</td>
</tr>
<tr>
<td></td>
<td>Deterioration of muscle proteins</td>
</tr>
<tr>
<td></td>
<td>Alterations in muscle macrophage function</td>
</tr>
<tr>
<td></td>
<td>Reduction of the actin-myosin bridges</td>
</tr>
<tr>
<td></td>
<td>Reduction in the number of sarcomers (serial and in parallel)</td>
</tr>
<tr>
<td>Hormonal and endocrine</td>
<td>Decreased levels of growth hormone, IGF-I, testosteron, dehydroepiandrosterone (DHEA), insulin, estradiol</td>
</tr>
<tr>
<td></td>
<td>Resistance to insulin action</td>
</tr>
<tr>
<td></td>
<td>Higher levels of parathyroid hormone</td>
</tr>
<tr>
<td></td>
<td>Higher levels of cortisol and leptin</td>
</tr>
<tr>
<td></td>
<td>Obesity (higher levels of IL-6; lower levels of testosteron and growth hormone, insulin resistance, intracellular deposits in muscle fibres, subclinical inflammation)</td>
</tr>
<tr>
<td>Humoral</td>
<td>Increase of abdominal fat</td>
</tr>
<tr>
<td></td>
<td>Higher levels of proinflammatory interleukins (IL-6, IL-1, TNF-α, TGF-β)</td>
</tr>
<tr>
<td></td>
<td>Lower levels of anti-inflammatory interleukins (IL-1ra, IL-1 receptor antagonist, IL-4, IL-10, IL-13)</td>
</tr>
<tr>
<td></td>
<td>Rise in soluble TNF receptor (sTNFR1)</td>
</tr>
<tr>
<td></td>
<td>Rise in C-reactive protein (CRP)</td>
</tr>
<tr>
<td></td>
<td>Increase in inflammation mediators (NF-κB, SOCS3, PGC-1, heat shock proteins, reactive oxygen and nitrogen species)</td>
</tr>
<tr>
<td>Apoptosis</td>
<td>Myostatin</td>
</tr>
<tr>
<td></td>
<td>Angiotensin II</td>
</tr>
<tr>
<td></td>
<td>Oxidative stress</td>
</tr>
<tr>
<td></td>
<td>Caspases</td>
</tr>
<tr>
<td></td>
<td>SRF (serum response factor)</td>
</tr>
<tr>
<td></td>
<td>Higher levels of neutrophils</td>
</tr>
<tr>
<td>Life style/Disease</td>
<td>Sedentarism</td>
</tr>
<tr>
<td></td>
<td>Smoking</td>
</tr>
<tr>
<td></td>
<td>Immobilization</td>
</tr>
<tr>
<td></td>
<td>Resting in bed</td>
</tr>
<tr>
<td>Nutrition</td>
<td>Chronic diseases</td>
</tr>
<tr>
<td></td>
<td>Malnutrition</td>
</tr>
<tr>
<td></td>
<td>Low intake of protein and essential aminoacids</td>
</tr>
<tr>
<td></td>
<td>Intake of low-quality proteins</td>
</tr>
<tr>
<td></td>
<td>Loss of appetite</td>
</tr>
<tr>
<td></td>
<td>Deficiency in vitamin D</td>
</tr>
<tr>
<td></td>
<td>Programming</td>
</tr>
<tr>
<td></td>
<td>Developmental plasticity</td>
</tr>
<tr>
<td></td>
<td>Phenotypical expression</td>
</tr>
<tr>
<td></td>
<td>Muscle proteins expression</td>
</tr>
<tr>
<td></td>
<td>Gene expression for proteolytic proteins (FOXO3A and MuRF-1)</td>
</tr>
</tbody>
</table>

activity. In fact, in the obese sarcopenic elder, physical exercise, together with a moderated caloric restriction, seems to be the optimal method to reduce fat mass and avoid the muscle mass wasting.

show a decrease in the protein metabolism, it is recommended that protein intake must be at least 1.0 to 1.3 g/kg body weight per day. This intake must be homogeneously distributed among all the meals during the day. Further, these proteins must show a high biological quality as higher content of branched-chain aminoacids (BCAA) such as leucine. Other nutritional measures such as antioxidant dietary supplementation, omega-3 acids or compensation of the vitamin D deficit have demonstrate to be efficient in the treatment of sarcopenia. These nutritional measures are very important when muscle catabolism increases because inactivity periods.

Regarding pharmacological procedures against sarcopenia, several pharmacological compounds have been used. However, their secondary effects and their moderated or null effect advise against their use in the treatment of muscle wasting. Some of these compounds such as angiotensin I to II-conversion inhibitors (ACE Inhibitors), simvastatin, androgenic receptor selective agonists, ibuprofen and paracetamol have demonstrated some efficacy in the treatment of sarcopenia. However, their definitive role in this pathology needs to be clarified.

Role of physical exercise in prevention and treatment of sarcopenia

Resistance exercise

Resistance exercise or muscle potentiation has demonstrated a great efficacy in the treatment and prevention of sarcopenia. In fact, increases in muscle mass, strength and quality and also a better neuromuscular adaptation have been reported after the practice of exercise programs including different exercise protocols. After analyzing the different recommendations of several associations such as the American College of Sport Medicine and the American Heart Association, and the results of the main studies performed about exercise, aging and sarcopenia, we suggest that the recommended exercise must contain resistance training including several exercises circuits with the 70-90% of the one repetition maximum (RM), with an exercise predominantly eccentric and performed, at least, every two non-consecutive days. Since the abondon of the resistance training ends in a fast waste of muscle mass, we advise that a maintenance exercise must be performed including, at least, a week session with the above indicated exercises and intensities. However, the clinical status of elderly people must be taken into consideration and obliges to individualize training programs.

Furthermore, several other added beneficial effects of resistance exercise to the health of elderly people must be taken into consideration. In fact, the practice of physical exercise also exerts a positive effect in the preservation of cognitive function.

Aerobic exercise

Aerobic exercise delays the strength loss and phenotypic changes produced during aging in muscle fibers, even at moderated intensities. However, the effects of aerobic exercise are modest and its definitive effect on sarcopenia is not completely clarified. Then, it seems clear that the combination of both, resistance and aerobic exercises is more healthy for elderly people since it produces multiple benefits preventing and treating prevalent diseases at old ages or in particular situations such as sarcopenic obesity.
Mechanisms of action of exercise on sarcopenia

There are multiple mechanisms by which resistance exercise prevents and ameliorates sarcopenia. We considered that it is worth to detail these mechanisms. Although these mechanisms are widely overlapped, we will analyze the effects of resistance exercise at muscle and neuromotor levels (fig. 1).

At the muscle level

At the muscle level, resistance exercise neutralizes several of the mechanisms involved in the development of sarcopenia. This kind of exercise induces positive changes in the inflammation status, apoptosis of muscle fibre, regeneration of these fibres and the function and anatomy of muscle. Regarding the function of muscle, resistance exercise increase muscle quality through the increase in the number of sarcomera in parallel but also serial number, by increase of the rigidity and the longitudinal elastic module (Young's module) of tendons.

Subclinical inflammation is one important etiological factor in sarcopenia. Resistance exercise reduces the chronic status of inflammation in elderly people by decreasing the level of pro-inflammatory mediators produced by monocytes/macrophages, increasing the production of anti-inflammatory cytokines or reducing the inflammatory response to acute exercise. Furthermore, resistance exercise also reduces the expression of genes encoding proteolytic proteins and increases the expression of antioxidant enzymes. Since the increase in fat mass and the reduction of the levels of sexual hormones is related to the increase of pro-inflammatory cytokines, the reduction of the amount of fat mass and infiltrated muscle fat by the practice of resistance exercise is other of the mechanisms by which exercise would reduce the chronic inflammatory status in elderly population showing sarcopenic obesity.

Apoptosis is other of the mechanisms involved in the development of muscle fibre loss during sarcopenia in the elderly. A session of acute exercise induces the apoptosis machinery in some of the muscle fibres. Moreover, this apoptosis is also a stimulus for the reparative machinery in muscle. For this reason, acute exercise also stimulates the process of muscle regeneration. When it is practiced regularly, exercise induces important and beneficial adaptations in apoptotic pathways such as a lower activity in caspases, lower amounts of proapoptotic proteins, increase of the expression of anti-apoptotic genes and increase in the levels of anti-apoptotic markers. Caloric restriction plays an important adjuvant role to the beneficial effects of exercise since it also contributes to the reduction of apoptosis in muscle fibers.

Mitochondrial dysfunction found in aged people is due to the accumulation of oxidative damage in mitochondria. This dysfunction jeopardizes the production of energy in muscle fibres and reduces the physical capacity in old people. Caloric restriction plays an important adjuvant role to the beneficial effects of exercise since it also contributes to the reduction of apoptosis in muscle fibers.

Reparation and regeneration mechanisms degenerate as years accumulate. One of the activation pathways in the regeneration of damaged muscle fibres depends on Insulin-like growth factor (IGF). The isoform I (IGF-I) promotes proliferation and differentiation of myoblasts and induces protein synthesis in muscle whereas the isoform II (IGF-II)
promotes the differentiation of satellite cells. Then, IGF benefits muscle recovery by stimulating anabolism in muscle fibres and activating proliferation and differentiation of satellite cells\textsuperscript{27,31}. In old people, muscle maintains the capacity to produce IGF-I, but shows resistance to its action. On the other hand, exercise increases the capacity to produce IGF-I, the synthesis of its receptors and the activity of the IGF-I-dependent pathways\textsuperscript{100,108-111}. Eccentric exercises, that at the beginning induce a higher muscle damage in comparison with concentric contraction, increase levels of IGF-I mRNA in muscle\textsuperscript{40}. Then, eccentric exercises will be especially indicated for the treatment of elderly people suffering sarcopenia. Other authors\textsuperscript{5} have related the increase in the sensibility to IGF-I and the decrease in the levels of homocystein produced by the practice of resistance exercise, with the prevention of cognitive decay induced by this type of exercise.

Since sarcopenia in the elderly affects predominantly to type II fibres and training of muscle strength, through vibratory platforms, increase the number of these fibres, this kind of training would be recommended for the treatment and prevention of sarcopenia, specially because its security, efficacy and simplicity\textsuperscript{112-115}. The physiological arguments of this methodology for training are based on the fact that the capacity of blunting of the vibratory stimulus depends on the viscoelastic properties of the individual. This means that this capacity depends on the stiffness produced by the structures of the organism and, in this case, this rigidity depends on the activation level of the receptors of the muscle use, the skin joints or on the proportion of muscle type II fibres in the person. These factors are compromised in different degree in elderly people\textsuperscript{116,117}. Other factors contributing to the increase of muscle stiffness are the incoordination agonist-antagonist\textsuperscript{118-121} and the increase in the rigidity of the tendons\textsuperscript{105}. These data would reinforce the use of vibrating platforms with subjects suffering sarcopenia.

**Neuromotor level**

After the performance of strength training programs the increase found in muscle strength is higher than the increase in muscle mass. This fact highlights the importance of the neuromuscular adaptations induced by this type of exercise. These adaptations consist in better muscle nervous stimuli from central nervous system, improvement of the synchronization\textsuperscript{122}, changes in the commitment\textsuperscript{118} and increase in muscle nervous stimuli and plasticity of synapse\textsuperscript{12}. Dynapenia, muscle weakness in the elderly, depends on alterations in muscle quantity, contractile quality and also neuronal activation. In this case, maintenance of the neuromuscular function through the practice of physical exercise seems to be essential for maintaining muscle strength and physical independence in old people\textsuperscript{129}.

**Molecular level**

Since muscle wasting indicates a deregulation of the mechanisms involved in the maintenance of muscle fibres, a better understanding of the metabolic processes involved in the regulation of muscle mass is critical. This knowledge will permit us to design and develop more effective therapies to prevent this process\textsuperscript{124}. Among the factors implicated in sarcopenia, the deregulation of muscle protein synthesis is one of the most frequently reported. Thus, the possible mechanisms to treat or prevent sarcopenia must include the regulation of the molecular factors that contribute to the balance between protein synthesis and breakdown\textsuperscript{125}. One of the main signalling pathways controlling protein synthesis in skeletal muscle is depending on the kinase Akt/PKB. One of the main targets of Akt/PKB is the mammalian target of rapamycin (mTOR) kinase that has been recently shown as a key sensor of nutritional status and lifespan. In fact, animal studies have demonstrated that Akt/ mTOR-dependent pathway is downregulated in muscle during aging\textsuperscript{126}. Furthermore, it has been demonstrated that this anabolic pathway show a delayed response to both, strength exercise and essential aminoacid treatment in aged in comparison with young people\textsuperscript{127}. These effects can probably due to the oxidative modification of Akt by s-nitrosylation that contributes to a lower activity and then, regulation of downstream targets even with higher levels of Akt\textsuperscript{124}. This delayed response is probably due to the insulin resistance that increases during aging since some experiments have demonstrated that supraphysiological doses of insulin can induce protein anabolism in muscle in aged people\textsuperscript{129}. Since aerobic exercise have demonstrated its capacity to overcome insulin-resistance in muscle\textsuperscript{130}, the combination of both, aerobic and strength exercise must increase the response of muscle and increase the activity of the Akt/mTOR dependent protein anabolism.

On the other hand, mitochondrial activity is other of the main factors involved in the maintenance of the activity of muscle fibres. Caloric restriction is one of the main therapies able to increase life-span and increase muscle capacity of the organisms tested during aging. This nutritional intervention prevents mitochondrial damage by improving the metabolic balance and avoiding oxidative stress\textsuperscript{131}. Then, a balanced aerobic metabolism will prevent mitochondrial damage and probably will delay sarcopenia progression. Thus, prevention of mitochondrial damage could be one of the key mechanisms to delay or avoid sarcopenia. Recently, studies performed in mouse models for mitochondrial mutations have demonstrated that exercise prevents mitochondrial dysfunction and apoptosis in sarcopenia by increasing mitochondrial remodeling\textsuperscript{132,133}, indicating the importance of functional mitochondria in muscle maintenance.

Biogenesis of mitochondria depends on multiple factors that converge in the activation of the peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α)\textsuperscript{34}. This factor is the centre of a system of gene induction that regulates the renovation of mitochondrial components and maintains mitochondria function. PGC-1α itself is regulated by several factors including AMP-activated protein kinase (AMPK). AMPK is a key sensor of the metabolism and nutritional status of the cell\textsuperscript{135}. Activity of AMPK is also negatively affected by aging contributing to the decrease of mitochondrial biogenesis and, then, sarcopenia. Furthermore, prevention of mitochondrial damage by increasing antioxidant activities has been recently shown to prevent age-associated mitochondrial function and improve insulin resistance\textsuperscript{136}. This fact will permit to maintain a better oxidative metabolism at the same time that improves protein anabolism by increasing insulin sensibility. However, in old organisms, mitochondrial biogenesis induced by exercise seems to be limited\textsuperscript{137}, although, some reports in humans indicate induction of this pathway at old ages\textsuperscript{138,139}, probably by inducing the activity of sirtuins, key factors in longevity and mitochondrial metabolism\textsuperscript{134,140,141}.

Finally, mitochondrial biogenesis must be balanced with the elimination of old and damaged mitochondria by mitophagy to maintain a balanced metabolism and avoid oxidative damage produced by higher release of reactive oxygen species (ROS). In this process, fork-head box
**Conclusions**

Resistance training, added to an adequate nutrition and aerobic exercise, is one of the main tools to prevent and treat sarcopenia in the elderly.

**References**

43. Bokov A, Chaudhuri A, Richardson A. The role of oxidative damage and inflammation in women occur at an earlier age than in men, but strength is preserved by hormone replacement therapy. Clin Sci. 1993;84:95-98.
47. Bokov A, Chaudhuri A, Richardson A. The role of oxidative damage and inflammation in women occur at an earlier age than in men, but strength is preserved by hormone replacement therapy. Clin Sci. 1993;84:95-98.
50. Bokov A, Chaudhuri A, Richardson A. The role of oxidative damage and inflammation in women occur at an earlier age than in men, but strength is preserved by hormone replacement therapy. Clin Sci. 1993;84:95-98.
53. Bokov A, Chaudhuri A, Richardson A. The role of oxidative damage and inflammation in women occur at an earlier age than in men, but strength is preserved by hormone replacement therapy. Clin Sci. 1993;84:95-98.


